PriceTargets.com logo

IGC Pharma - IGC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 955.41%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.38 As of 12/20/2024 01:00 AM ET
▲ +0.011 (2.99%)

This chart shows the closing price for IGC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IGC Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IGC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IGC

Analyst Price Target is $4.00
▲ +955.41% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for IGC Pharma in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 955.41% upside from the last price of $0.38.

This chart shows the closing price for IGC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in IGC Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/5/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$3.75 ➝ $4.00
9/3/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$3.50 ➝ $3.75
(Data available from 12/23/2019 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

IGC Pharma

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
Read More

Today's Range

Now: $0.38
Low: $0.33
High: $0.38

50 Day Range

MA: $0.38
Low: $0.33
High: $0.41

52 Week Range

Now: $0.38

Volume

737,575 shs

Average Volume

419,180 shs

Market Capitalization

$29.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of IGC Pharma?

The following Wall Street analysts have issued stock ratings on IGC Pharma in the last year: Ascendiant Capital Markets.
View the latest analyst ratings for IGC.

What is the current price target for IGC Pharma?

0 Wall Street analysts have set twelve-month price targets for IGC Pharma in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 955.4%. Ascendiant Capital Markets has the highest price target set, predicting IGC will reach $4.00 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $4.00 for IGC Pharma in the next year.
View the latest price targets for IGC.

What is the current consensus analyst rating for IGC Pharma?

IGC Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IGC will outperform the market and that investors should add to their positions of IGC Pharma.
View the latest ratings for IGC.

What other companies compete with IGC Pharma?

Other companies that are similar to IGC Pharma include Regulus Therapeutics, Tribute Pharmaceuticals Canada, MediciNova, Journey Medical and Skye Bioscience. Learn More about companies similar to IGC Pharma.

How do I contact IGC Pharma's investor relations team?

IGC Pharma's physical mailing address is 10224 Falls Road, Potomac, MD 20854, United States. The company's listed phone number is (301) 983-0998 and its investor relations email address is [email protected]. The official website for IGC Pharma is igcpharma.com. Learn More about contacing IGC Pharma investor relations.